Tarsus Pharmaceuticals, Inc.'s (NASDAQ:TARS) Shift From Loss To Profit
Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) is possibly approaching a major achievement in its business, so we would like to shine some light on the company. Tarsus Pharmaceuticals, Inc., a
When Will Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Turn A Profit?
BofA Securities Maintains Tarsus Pharmaceuticals(TARS.US) With Buy Rating
BofA Securities analyst Jason Gerberry maintains $Tarsus Pharmaceuticals(TARS.US)$ with a buy rating.According to TipRanks data, the analyst has a success rate of 44.4% and a total average return of -
Express News | Tarsus Pharmaceuticals Inc : BofA Global Research Cuts Price Objective to $61 From $63
Small-cap, Buy-rated Stocks With Positive Estimate Revision Factors - BofA
Most Shareholders Will Probably Agree With Tarsus Pharmaceuticals, Inc.'s (NASDAQ:TARS) CEO Compensation
Key Insights Tarsus Pharmaceuticals' Annual General Meeting to take place on 13th of June Salary of US$619.5k is part of CEO Bobby Azamian's total remuneration The overall pay is 49% below the ind
Tarsus to Participate in Upcoming Investor Conferences
IRVINE, Calif., May 29, 2024 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS), whose mission is to focus on unmet needs and apply proven science and new technology to revolutionize treatment for patients,
12 Health Care Stocks Moving In Monday's Pre-Market Session
GainersTevogen Bio Holdings (NASDAQ:TVGN) stock rose 55.4% to $1.53 during Monday's pre-market session. The market value of their outstanding shares is at $251.8 million. MiNK Therapeutics (NASDAQ:INK
Analysts Are Betting On Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) With A Big Upgrade This Week
Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) shareholders will have a reason to smile today, with the analysts making substantial upgrades to this year's forecasts. The analysts have sharply increased
Express News | Tarsus Pharmaceuticals, Inc. : H.c. Wainwright Raises Target Price to $61 From $57
Express News | Tarsus Pharmaceuticals Inc : Jefferies Raises Target Price to $48 From $46
Tarsus Pharmaceuticals Is Maintained at Overweight by Barclays
Tarsus Pharmaceuticals Is Maintained at Overweight by Barclays
Express News | Barclays Maintains Overweight on Tarsus Pharmaceuticals, Raises Price Target to $60
Express News | Tarsus Pharmaceuticals : Barclays Raises Target Price to $60 From $50
Analysts Offer Insights on Healthcare Companies: Tarsus Pharmaceuticals (TARS), Collegium Pharmaceutical (COLL) and Intellia Therapeutics (NTLA)
Tarsus to Participate in Fireside Chat at the 2024 Bank of America Healthcare Conference
IRVINE, Calif., May 09, 2024 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS), whose mission is to focus on unmet needs and apply proven science and new technology to revolutionize treatment for patients,
Tarsus Pharmaceuticals Is Maintained at Outperform by Oppenheimer
Tarsus Pharmaceuticals Is Maintained at Outperform by Oppenheimer
Tarsus Pharmaceuticals Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 05/09/2024 43.16% Oppenheimer $59 → $61 Maintains Outperform 03/06/2024 3.26% Jefferies $30 → $44 Maintain
Earnings Call Summary | Tarsus Pharmaceuticals(TARS.US) Q1 2024 Earnings Conference
The following is a summary of the Tarsus Pharmaceuticals, Inc. (TARS) Q1 2024 Earnings Call Transcript:Financial Performance:Tarsus reported $27.6 million in total revenue, made up of $24.7 million in
Oppenheimer Adjusts Tarsus Pharmaceuticals Price Target to $61 From $59, Maintains Outperform Rating
Tarsus Pharmaceuticals (TARS) has an average rating of Buy and price targets ranging from $30 to $67, according to analysts polled by Capital IQ. Price: 35.83, Change: -1.52, Percent Change: -4.07